Edgewise Therapeutics Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.03 (market cap $3.94B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.7× Edgewise Therapeutics Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| EWTX | PCVX | |
|---|---|---|
Market Cap | $3.94B | $10.51B |
Volume | 810,104 | 2,644,694 |
Sector | Health | Health |
52-Week High | $48.35 | $73.82 |
52-Week Low | $14.89 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.48B | $9.14B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →